Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines

In 2003 a consensus group on new-generation antihistamines (CONGA) defined the characteristics required for a third-generation H1 antihistamine as there had been much controversy about this issue since the early 1990s. One of the antihistamines that had been claimed to belong to such a group is the second-generation antihistamine, ebastine. The objective of this review is to analyze the pharmacology of ebastine, in light of the CONGA recommendations for the development of new-generation antihistamines: (1) anti-inflammatory properties, (2) potency, efficacy and effectiveness, (3) lack of cardiotoxicity, (4) lack of drug interactions, (5) lack of CNS effects, and (6) pharmacological approach. Ebastine seems to have anti-inflammatory properties that help to ameliorate nasal congestion, though this has not yet been conclusively demonstrated. Its pharmacological–therapeutic profile does not differ greatly from that of other second-generation antihistamines. Its cardiac safety has been widely assessed and no cardiac toxicity has been found at therapeutic doses despite initial concerns. The risk of potentially relevant drug interactions has been investigated and ruled out. Ebastine does not produce sedation at therapeutic doses and drug interaction studies with classical CNS depressants have not demonstrated a synergistic effect. Pharmacologically, ebastine is an H1 inverse agonist. Perhaps the answer to the quest for new-generation antihistamines lies not only in H1 but in a combined approach with other histamine receptors.

[1]  J. Bousquet,et al.  A 12‐week, placebo‐controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis , 1999, Allergy.

[2]  M. Molina,et al.  Efficacy and Tolerability of Ebastine at Two Dose Levels in the Treatment of Seasonal Allergic Rhinitis , 1989 .

[3]  H. Wiemann,et al.  Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG , 2004, European Journal of Clinical Pharmacology.

[4]  C. Serra,et al.  Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. , 2007, Clinical therapeutics.

[5]  Holger Stark,et al.  Histamine H3 receptor antagonists go to clinics. , 2008, Biological & pharmaceutical bulletin.

[6]  F. Hampel,et al.  A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. , 2004, Journal of investigational allergology & clinical immunology.

[7]  R. June,et al.  Torsades de pointes with terfenadine ingestion. , 1997, The American journal of emergency medicine.

[8]  M. Mattila,et al.  Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine. , 1993, British journal of clinical pharmacology.

[9]  Wiklund Ra,et al.  First of two parts , 1997 .

[10]  N. Papadopoulos,et al.  Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. , 2001, The Journal of allergy and clinical immunology.

[11]  Kwang-Hyeon Liu,et al.  Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A , 2006, Drug Metabolism and Disposition.

[12]  Jagdish,et al.  Occurrence of torsade de pointes with use of astemizole. , 1994, Indian heart journal.

[13]  J. Zayas,et al.  Ebastine in chronic urticaria: A double-blind placebo-controlled study , 1991 .

[14]  R. Davies,et al.  Efficacy and Tolerability Comparison of Ebastine 10 and 20mg with Loratadine 10mg , 1998 .

[15]  T. Horiguchi,et al.  Effect of Ebastine on Serum Eosinophil Cationic Protein Levels in Patients with Bronchial Asthma , 1999 .

[16]  J. Mullol,et al.  Interactions of the H1 antihistamines. , 2006, Journal of investigational allergology & clinical immunology.

[17]  D. Argenti,et al.  Pharmacokinetics and Electrocardiographic Effect of Ebastine in Young Versus Elderly Healthy Subjects , 1998, American journal of therapeutics.

[18]  F. Horak.  Impact and modulation of nasal obstruction , 2002, Allergy.

[19]  A. Didier,et al.  Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  R. Antonijoan,et al.  Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[21]  K. Yoneda,et al.  Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. , 1997, Japanese journal of pharmacology.

[22]  J. Hey,et al.  Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80. , 2005, Life sciences.

[23]  M. Asakura,et al.  Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. , 1995, Methods and findings in experimental and clinical pharmacology.

[24]  P. Clement,et al.  Comparison of five new antihistamines (H1‐receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests , 2002, Allergy.

[25]  M. Humbert,et al.  H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. , 2007, The Journal of allergy and clinical immunology.

[26]  D. Roberts.  Towards the optimal antihistamine: Studies with ebastine , 1998, Inflammation Research.

[27]  A. Moss,et al.  A review of the cardiac systemic side‐effects of antihistamines: ebastine , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  H. Arai,et al.  Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. , 2002, British journal of clinical pharmacology.

[29]  S. Matsumoto,et al.  Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats. , 1994, Arzneimittel-Forschung.

[30]  G. Ciprandi,et al.  Ebastine increases IFN-gamma production in patients with persistent allergic rhinitis. , 2009, Journal of biological regulators and homeostatic agents.

[31]  P. Van cauwenberge,et al.  A review of the second-generation antihistamine ebastine for the treatment of allergic disorders , 2004, Expert opinion on pharmacotherapy.

[32]  S. Hill,et al.  Role of Protein Kinase Cα in Signaling from the Histamine H1 Receptor to the Nucleus , 2001 .

[33]  J. Boyle,et al.  Sedation and antihistamines: an update. Review of inter‐drug differences using proportional impairment ratios , 2008, Human psychopharmacology.

[34]  W. König,et al.  Cetirizine counter‐regulates interleukin‐8 release from human epithelial cells (A549) , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  M. Taglialatela,et al.  Cardiotoxic effects of antihistamines: from basics to clinics (...and back). , 2008, Chemical research in toxicology.

[36]  X. Luria,et al.  Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. , 2004, European journal of internal medicine.

[37]  D. Bovet.  INTRODUCTION TO ANTIHISTAMINE AGENTS AND ANTERGAN DERIVATIVES , 1950 .

[38]  M. Mathieu,et al.  Histamine H1‐receptor antagonists inhibit nuclear factor‐kappaB and activator protein‐1 activities via H1‐receptor‐dependent and ‐independent mechanisms , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[39]  J. Gras,et al.  Effects of H1 Antihistamines on Animal Models of QTc Prolongation , 1999, Drug safety.

[40]  M. Artés,et al.  Ebastine fast-dissolving tablets versus regular tablets: acceptability and preference in patients with allergic rhinitis , 2008, Expert review of clinical pharmacology.

[41]  T. Reunala,et al.  Treatment of mosquito bites with ebastine: a field trial. , 2000, Acta dermato-venereologica.

[42]  E. Schulman,et al.  Pharmacologic characterization of a novel histamine receptor on human eosinophils. , 1994, American journal of respiratory and critical care medicine.

[43]  T. Inaba,et al.  N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[44]  F P Rivara,et al.  Occupational injuries and medication use. , 1996, American journal of industrial medicine.

[45]  M Malik,et al.  Problems of Heart Rate Correction in Assessment of Drug‐Induced QT Interval Prolongation , 2001, Journal of cardiovascular electrophysiology.

[46]  F. Di Virgilio,et al.  Expression and function of histamine receptors in human monocyte-derived dendritic cells. , 2002, The Journal of allergy and clinical immunology.

[47]  R. Woosley,et al.  Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.

[48]  N. Frossard,et al.  Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers , 2000, Fundamental & clinical pharmacology.

[49]  M. Mattila,et al.  Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects , 2005, European Journal of Clinical Pharmacology.

[50]  S. C. Armstrong,et al.  Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. , 2003, Psychosomatics.

[51]  A. Zechnich,et al.  Second-generation antihistamines: a comparative review. , 1999, Drugs.

[52]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[53]  M. Rottem.  [Allergic rhinitis and its impact on asthma]. , 2010, Harefuah.

[54]  M. Nakashima,et al.  Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. , 1994, Arzneimittel-Forschung.

[55]  R. Clark,et al.  The selective eosinophil chemotactic activity of histamine , 1975, The Journal of experimental medicine.

[56]  Lars Karlsson,et al.  A Potent and Selective Histamine H4 Receptor Antagonist with Anti-Inflammatory Properties , 2004, Journal of Pharmacology and Experimental Therapeutics.

[57]  C. Picado Vallés,et al.  Ebastine in perennial allergic rhinitis. , 1991, Annals of allergy.

[58]  O. Inchley.  Histamine shock , 1926, The Journal of physiology.

[59]  L. Crampette,et al.  Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. , 1996, Drugs.

[60]  D De Waard,et al.  Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. , 1993, British journal of clinical pharmacology.

[61]  G. Rhodes,et al.  Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. , 2005, British journal of clinical pharmacology.

[62]  R. Egan,et al.  Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[63]  P. Ratner,et al.  Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. , 2000, The Journal of allergy and clinical immunology.

[64]  C. Akdis.  New insights into mechanisms of immunoregulation in 2007. , 2008, The Journal of allergy and clinical immunology.

[65]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[66]  R. Davies,et al.  Allergen/irritant interaction ‐ its role in sensitization and allergic disease , 1998, Allergy.

[67]  S. Iwata,et al.  Ebastine inhibits T cell migration, production of Th2‐type cytokines and proinflammatory cytokines , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[68]  T. Zuberbier,et al.  Acquired cold urticaria symptoms can be safely prevented by ebastine , 2007, Allergy.

[69]  M. Morad,et al.  Suppression of mammalian K+ channel family by ebastine. , 1997, The Journal of pharmacology and experimental therapeutics.

[70]  F. Hampel,et al.  Efficacy and Safety of Ebastine 20 mg Compared to Loratadine 10 mg Once Daily in the Treatment of Seasonal Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Study , 2004, International Archives of Allergy and Immunology.

[71]  A. Reig,et al.  Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectancies. , 2006 .

[72]  P. Fireman.  Treatment of allergic rhinitis: effect on occupation productivity and work force costs. , 1997, Allergy and asthma proceedings.

[73]  M. Malik.  Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. , 2002, British journal of clinical pharmacology.

[74]  J. Mullol,et al.  Comparative pharmacology of the H1 antihistamines. , 2006, Journal of investigational allergology & clinical immunology.

[75]  C. Picado,et al.  A Review of its Pharmacological Properties and Clinical Efficacy in the Treatment of Allergic Disorders , 1996 .

[76]  J. O'hanlon,et al.  Seasonal allergic rhinitis and antihistamine effects on children's learning , 1992, European Neuropsychopharmacology.

[77]  J. Hanifin,et al.  The role of antihistamines in atopic dermatitis. , 1990, The Journal of allergy and clinical immunology.

[78]  S. C. Armstrong,et al.  Med-psych drug-drug interactions update. , 2001, Psychosomatics.

[79]  I. Hindmarch,et al.  The Effects of Single and Repeated Administration of Ebastine on Cognition and Psychomotor Performance in Comparison to Triprolidine and Placebo in Healthy Volunteers , 2001, Current medical research and opinion.

[80]  R. Egan,et al.  Combined Histamine H1 and H3 Receptor Blockade Produces Nasal Decongestion in an Experimental Model of Nasal Congestion , 1999, American journal of rhinology.

[81]  D. Roberts.  A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist. , 1996, Drugs.

[82]  S. Imaoka,et al.  A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[83]  N. Okamura,et al.  New findings in pharmacological effects induced by antihistamines: from PET studies to knock‐out mice , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[84]  P. Desai,et al.  Histamine H4 Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[85]  V. Segarra,et al.  Computer-Assisted Comparison of the Structural and Electronic Dispositions of Ebastine and Terfenadine , 1999, Drug safety.

[86]  R. Antonijoan,et al.  A Study Comparing the Inhibitory Effects of Single and Repeated Oral Doses of Ebastine and Fexofenadine against Histamine-Induced Skin Reactivity , 2003, International Archives of Allergy and Immunology.

[87]  Y. Sai,et al.  Blood-Brain Barrier Transport of H1-Antagonist Ebastine and its Metabolite Carebastine , 2000, Journal of drug targeting.

[88]  G. W. Canonica,et al.  Consensus group on new‐generation antihistamines (CONGA): present status and recommendations , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[89]  Huiyuan Ya.  Advances in H1-antihistamines , 2006 .

[90]  P. Ratner,et al.  Meta-Analysis of the Efficacy of Ebastine 20 mg Compared to Loratadine 10 mg and Placebo in the Symptomatic Treatment of Seasonal Allergic Rhinitis , 2005, International Archives of Allergy and Immunology.

[91]  H M Simpson,et al.  Incidence and toxicological aspects of drugs detected in 484 fatally injured drivers and pedestrians in Ontario. , 1982, Journal of forensic sciences.

[92]  R. Egan,et al.  The guinea pig model for assessing cardiotoxic proclivities of second generation antihistamines. , 1996, Arzneimittel-Forschung.

[93]  P. Géhanno,et al.  Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[94]  T. Williams,et al.  Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor , 2003, British journal of pharmacology.

[95]  R. Egan,et al.  Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. , 1996, Arzneimittel-Forschung.

[96]  J. Sastre.  Ebastine in allergic rhinitis and chronic idiopathic urticaria , 2008, Allergy.

[97]  E. Schulman,et al.  Mast cell mediators prostaglandin-D2 and histamine activate human eosinophils. , 1992, Journal of immunology.

[98]  R. Thurmond,et al.  Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation , 2004, British journal of pharmacology.

[99]  L. Wiseman,et al.  Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. , 1996, Drugs.

[100]  S. Ankier,et al.  A double‐blind placebo‐controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients , 1989, Journal of internal medicine.

[101]  A. Drake-lee,et al.  Increase in epithelial mast cell numbers in the nasal mucosa of patients with perennial allergic rhinitis , 1996, The Journal of Laryngology & Otology.

[102]  J. Palacios,et al.  The role of ketoconazole in the QTc interval prolonging effects of H1‐antihistamines in a guinea‐pig model of arrhythmogenicity , 1996, British journal of pharmacology.

[103]  C. PicadoVallés,et al.  Ebastine in perennial allergic rhinitis. , 1991 .

[104]  Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. , 1993, British journal of clinical pharmacology.

[105]  C. Kamei,et al.  Pruritus‐associated response mediated by cutaneous histamine H3 receptors , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[106]  R. Spector,et al.  Transport of diphenhydramine in the central nervous system. , 1987, The Journal of pharmacology and experimental therapeutics.

[107]  M. Valle,et al.  A Comparison of Ebastine 10mg Fast-Dissolving Tablet with Oral Desloratadine and Placebo in Inhibiting the Cutaneous Reaction to Histamine in Healthy Adults , 2007, Clinical drug investigation.

[108]  R Iwata,et al.  Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. , 2001, British journal of clinical pharmacology.

[109]  S. C. Armstrong,et al.  Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. , 2003, Psychosomatics.

[110]  Nicholas J. Carruthers,et al.  Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. , 2001, Molecular pharmacology.

[111]  J. Gras,et al.  Comparative Antiallergic Effects of Second-generation H1-Antihistamines Ebastine, Cetirizine and Loratadine in Preclinical Models , 2003, Arzneimittelforschung.

[112]  Erwin W. Gelfand,et al.  The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines , 2008, Nature Reviews Drug Discovery.

[113]  Howarth.  Assessment of antihistamine efficacy and potency , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[114]  R. Leurs,et al.  Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. , 2001, Molecular pharmacology.

[115]  M. Artés,et al.  Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis , 2008, Expert review of pharmacoeconomics & outcomes research.

[116]  J. Vincent,et al.  Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. , 1988, British journal of clinical pharmacology.

[117]  Y. Masuho,et al.  Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes* , 2000, The Journal of Biological Chemistry.

[118]  W. Fokkens,et al.  Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non‐allergic controls: a biopsy study , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[119]  Philip D. Harvey,et al.  First do no harm: managing antihistamine impairment in patients with allergic rhinitis. , 2003, The Journal of allergy and clinical immunology.

[120]  M. Mattila,et al.  Variations among non-sedating antihistamines: are there real differences? , 1999, European Journal of Clinical Pharmacology.

[121]  C. Spencer,et al.  Ebastine , 2000, Drugs.

[122]  A B Kay,et al.  Allergy and allergic diseases. First of two parts. , 2001, The New England journal of medicine.

[123]  S. Hill,et al.  Role of protein kinase Calpha in signaling from the histamine H(1) receptor to the nucleus. , 2001, Molecular pharmacology.

[124]  M. Artés Ferragud,et al.  Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectancies. , 2006, Allergologia et immunopathologia.

[125]  P. Kao,et al.  Leukotriene B4 mediates histamine induction of NF-κB and IL-8 in human bronchial epithelial cells. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[126]  R. Egan,et al.  Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. , 1996, Arzneimittel-Forschung.